Table 2.
Most common treatment-related adverse events of different myotic drugs (TRAE).
|
Drug |
Duration of action | TRAE |
|||||
|---|---|---|---|---|---|---|---|
| Conjunctival hyperaemia | Eye irritation | Eye pain | Vision impairment | Headache | Severity of TRAE | ||
| Pilocarpine HCl 1.25% (VUITY) | Once daily - 6 h | 5.1% | – | 4.3% | 4.5% | 14.9% | |
| Twice daily - 9 h | 6.1% | – | 2.6% | 6.1% | 8.8% | 82% mild. None severe | |
| Pilocarpine 0.4 (CSF-1) | 6-8 | 1.6% | – | 5.8% | 3.6% | 6.8% | 96.1% mild. None severe |
| Phentolamine + Pilocarpine | 6 | 4.55% | 6.82% | 2.27% | 2.27% | 0% | None severe |
| Carbochol + Brimonidine (Brimochol) | 6–8 | – | – | 14.04% | – | 8.99% | 0.56% severe (nephrolithiasis) |
| Aceclinide + Brimonidine (LNZ100) | 10 | 9.0% | 20.1% | 13.2% | 11.5% | Mild | |